Opdivo delivers significant OS and PFS benefits in CheckMate -649 trial

This article was originally published here

The CheckMate -649 trial demonstrated statistically significant and clinically meaningful improvement in both the parameters for the Opdivo + chemotherapy arm compared to chemotherapy alone. The late-stage trial

The post Opdivo delivers significant OS and PFS benefits in CheckMate -649 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply